98%
921
2 minutes
20
Basal ganglia injury (BGI) is a type of perinatal hypoxic-ischemic (H-I) brain injury. Both malfunctions of glutamatergic and dopaminergic pathways in striatum were suggested to contribute to BGI. In current study, we investigated the imaging profile of glutamate (Glx) levels by proton magnetic resonance spectroscopy ((1)H-MRS), and the expression of dopamine D2 receptors (D2R) and dopamine transporter (DAT) by immunohistochemical staining in a newborn piglet model of H-I brain injury. We found that the number of striatal D2R positive neurons decreased following H-I brain injury, and the decrease in positive neuron number was consistent with the degree of striatum. Following H-I brain insult, the number of striatal DAT positive neurons and glutamate level were simultaneously increased initially, followed by a gradual decline toward control level. There was a positive correlation between the changes in striatal DAT positive neurons and glutamate level following H-I brain insults in newborn piglets. Our findings suggest that following H-I brain insult, striatal D2R positive neurons decreased due to neuron death; straital DAT initially increased to compensate for dopamine uptake; and glutamatergic and dopaminergic systems in striatum may act in an interdependent way in the striatum of newborn piglets.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejpn.2011.05.010 | DOI Listing |
PLoS One
August 2025
School of Information and Data Sciences, Nagasaki University, Nagasaki, Japan.
Introduction: Diagnosing neuropsychiatric systemic lupus erythematosus (NPSLE) and differentiating it from systemic lupus erythematosus (SLE) without neuropsychiatric manifestations remains a substantial clinical challenge due to the absence of specific biomarkers. Topological data analysis (TDA) is a novel computational technique that enables the visualization, exploration, and analysis of complex data structures. This study aimed to identify distinct neuroimaging biomarkers in patients with NPSLE (NPSLE group) and differentiate them from patients with SLE without neuropsychiatric symptoms (non-NPSLE group) by employing TDA.
View Article and Find Full Text PDFEBioMedicine
August 2025
Novo Nordisk A/S, Research and Early Development, Måløv, Denmark. Electronic address:
Background: Amycretin is a novel unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist. This study aimed to determine its role in mitigating diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty liver disease, in mice and rats.
Methods: Preclinical studies were conducted to characterise amycretin activation of GLP-1, amylin and calcitonin receptors, and determine the effects of amycretin administration on the metabolic health of mice and rats.
Nat Commun
July 2025
Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by alterations in social, repetitive, and anxiety-like behaviors. While emerging evidence suggest a gut-brain etiology in ASD, the underlying mechanisms remain unclear. To dissect this axis, we developed a germ-free BTBR mouse model for ASD.
View Article and Find Full Text PDFActa Neuropathol Commun
July 2025
Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.
Neonatal hypoxic-ischemic (H-I) brain injury, a leading cause of neurodevelopmental disabilities, severely affects the metabolically active and neurogenic hippocampus. To investigate its acute effects and identify drug targets for early therapeutic windows, we applied single-nucleus RNA sequencing on postnatal day 8 (P8) mouse hippocampi under sham, hypoxic, and hypoxic-ischemic conditions. We constructed a comprehensive hippocampal cell atlas and developed a machine-learning classifier for precise cell type identification.
View Article and Find Full Text PDFGeriatr Nurs
August 2025
Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
Recently, the Food and Drug Administration (FDA) approved the use of aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) in patients with mild cognitive impairment (MCI) and early-stage dementia secondary to Alzheimer's disease (AD). These medications-classified as anti-amyloid immunotherapies-reduce the burden of amyloid in the brain, as well as clinical decline as evidenced by cognitive assessments. Amyloid Related Imaging Abnormalities (ARIA), including ARIA-E (i.
View Article and Find Full Text PDF